Abeona Therapeutics (ABEO): JAMA Offers Detail On EB-101 Phase I Results - FBR

November 30, 2016 8:18 AM EST Send to a Friend
FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Abeona Therapeutics (NASDAQ: ABEO) after closely reviewing results ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login